Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Endocare Inc.

Division of Varian Medical Systems Inc.

Latest From Endocare Inc.

The A-List: 2009's Trend-Shaping Series A Financings

New company creation slipped significantly in 2009 as venture capitalists conserved capital and supported existing portfolio companies. In biopharmaceuticals, corporate venture got in at the ground floor while device start-ups continued to see stronger support from smaller, regional investors than traditional VCs.
BioPharmaceutical Medical Device

The A-List: 2008's Trend Shaping Series A Financings

Despite a miserable economy, new company formation continues apace. In biotech, recapitalizations and structured deals featured prominently; in diagnostics, interest remains strong even if rounds in 2008 were down from last year's highs; in devices, small and regional VCs have filled the void left by brand-name investors.
BioPharmaceutical Medical Device

The Golden Age in Cancer Medtech Investing

Short of investing in the kinds of products that must demonstrate five-year survival rates, the field of cancer offers many near term investment opportunities, and large markets to support them. As noted in US Disease Incidence and Prevalence, a report recently published by the Medtech Insight division of FDC-Windhover, like many diseases, the incidence of cancer increases with age. More than 10.8 million people in the US have a history of cancer; and in 2008, at least 1.4 million more people will be diagnosed. According to the Medtech Insight report, breast cancer has the highest prevalence rate, followed by prostate and colorectal cancers.
Medical Device

European Markets for Benign Prostatic Hyperplasia Therapies

Investor interest in the urology space waxes and wanes; it's attractive because as a niche specialty it has some pretty big patient populations. Benign prostatic hyperplasia (BPH), the benign enlargement of the prostate over time, affects 90% of men by the time they're 80, and half of men at age 60. In Europe, according to European Markets for Benign Prostatic Hyperplasia Drugs, Devices, and Therapies, a report recently published by FDC-Windhover Information's Medtech Insight division, that's 28 million men. But urology goes out of favor from time to time because so many drugs and device therapies that initially looked promising failed to address the majority of BPH sufferers, or worse, caused side effects in a very sensitive part of the body. Now, we seem to be heading into an up-cycle for BPH, in both the device and pharmaceutical segments.
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Varian Medical Systems Inc.
  • Senior Management
  • David Chen, CEO
  • Contact Info
  • Endocare Inc.
    Phone: (877) 467-2009
    9825 Spectrum Dr.
    Bldg. 2
    Austin, TX 78717